忠

诚

责任

严谨

创新

关爱

服务

团队

沟通

公司概况

COMPANY
PROFILE

创建于2005年7月，

总部坐落于美丽的深圳湾畔，后海之滨；

集团拥有员工800多名， 其中40%以上为技术研发人员；

是我国最早专业从事战略性新兴产业生物治疗技术临床转化及技

术服务的国家级高新技术企业。

深圳市北科生物科技有限公司

（以下简称：北科生物）

Shenzhen Beike Biotechnology Co., Ltd

(hereinafter referred to as Beike)

Founded in July 2005,

Headquartered in Houhai at the beautiful Shenzhen bay;

More than 800 employees, of which more than 40% are research and

development personnel;

China's earliest national high-tech enterprise specializing in the strategic

emerging industries of clinical translation and technical service of

biological treatment technologies.

北科总部及国际干细胞研发基地

01

严 谨 · 创 新 · 关 爱 · 服 务

02

申请132项细胞技术领域相关专利，106项获得授权；

在国内外包括Cell Stem Cell等权威杂志发表论文100余篇；

承担各级政府项目60余项，其中6项国家级项目（2项863项目）。

Application of 132 cell field-related patents, with 106already approved;

Published more than 100 articles at authoritative domestic and

international journals, including Cell Stem Cell;

Commitment to more than 60 government projects at all levels, of which 6

are state-level projects (including two 863 projects).

03 创始⼈

THE
FOUNDER

Dr. Sean Hu

Founder and Chairman of

Beike Biotechnology

北科生物创始人、董事长

胡隽源博士

●国家干细胞与再生医学产业技术创新战略联盟副理事长

●深圳市国家级领军人才

●雄安国际健康论坛执行主席

●博鳌亚洲论坛世界生命科学论坛发起人

●联合国儿童基金会国际顾问委员会委员

●深圳市干细胞工程技术研究开发中心主任

●改革开放40年影响中国的深商领袖之一

● Vice Chairman, the China National Technology Innovation Strategic

Alliance of Stem Cell and Regenerative Medicine Industry

● A National Leading Talent in Shenzhen

● Executive Chairman, Xiongan International Health Forum

● Promoter of the World Life Science Forum at Boao Forum for Asia

● A member of the International Council of the United Nations Children's Fund

● Director-General, Shenzhen Stem Cell Engineering Technology Research and

Development Center

● One of the Shenzhen business leaders who influenced China in the 40 years of

reform and opening up

战略平台

STRATEGIC
PLATFORM

综合细胞库暨区域细胞制备中心网络

“铺设”一条既能满足临床需求及时性又兼顾生产规模化，联通临床需求方

和先进技术供给方的“细胞治疗高速公路网”，已形成覆盖华南、华东、华

中、华北、西南、西北的个体化细胞治疗产业公共技术服务平台。为细胞治

疗技术临床转化提供创新性的公共技术平台和基础设施，为我国细胞治疗产

业发展模式提供一条可借鉴的创新之路。

Network for Cell Banks and Regional Cell Manufacturing Centers

By laying out a “cell therapy expressway network” that can meet clinical needs

including quantity, quality and timeliness, it provides an innovative public

technology platform and infrastructure for clinical translation of cell therapy

technologies.It already covers all major regions of China and is achieving

outstanding results, providing a new way for China's cell therapy industry to

develop.

严 谨 · 创 新 · 关 爱 · 服 务

04

05 服务于各区域战略需求的科研和产业基础设施，解决各区域由于缺乏综合细胞库，从而限制不同来

源细胞治疗技术的研究、开发和产业化发展的问题。在北科生物严格的建库标准下，将多种组织来

源（脐带、胎盘、脂肪、乳牙、子宫蜕膜等）成体干细胞、IPS细胞、免疫细胞等宝贵细胞资源进

行储存，为难治性疾病的治疗、急性损伤修复和药物筛选等多个方面提供强力支持！

As research and industrial infrastructures serving the strategic needs of every region, it addresses the problems

that impact research, development and industrialization of Cell therapy technologies caused by the lack of

integrated cell banks. Under Beike's strict cell bank standards, stem cells from different tissues (such as

umbilical cord, bone marrow, placenta, fat, deciduous teeth, decidua and more), iPS cells, immune cells and

other precious cells are stored, providing strong support for various procedures, including treatment of

refractory diseases, recovery from acute injuries and drug screening.

Integrated cell Bank

综合细胞库

严 谨 · 创 新 · 关 爱 · 服 务

06

北科生物的大型区域细胞制备中心设于广东深圳、江苏泰州、河北石家庄、江西南

昌、贵州贵阳，包括细胞制备区、检测区、行政辅助区等独立功能区，配套流式细胞

仪等国际先进的仪器设备。中心着重双特异抗体免疫细胞、多抗原诱导免疫细胞、细

胞储存等技术的自主开发，构筑细胞治疗基础研究、临床科研及临床应用基地，实现

个体化细胞治疗技术的产业化。

区域细胞制备中心

Beike Biotechnology has situated large regional manufacturing facilities for personalized Cell

therapy in Shenzhen (Guangdong), Taizhou (Jiangsu), Shijiazhuang (Hebei), Nanchang (Jiangxi) and

Guiyang(Guizhou)which have independent functional areas including cell preparation, testing and

administration, and are equipped with advanced apparatuses. These centers develop technologies of

bi-specific antibody immune cells, multi-antigen-induced immune cells and stem cell storage,

establishing a fundamental base for cell therapies,clinical research and application,and

industrialization of personalized cell therapy technologies.

Regional cell Manufacturing Center

各区域建立生物治疗所需的各类细胞制品的制造、检验、鉴定等为一体的综合性细胞生物技术转化应用平台。定位：

建立严格的质量控制和评价体系，确保细胞制备的均一性、稳定性、可控性、有效性和可追溯性，促进最新的生物治疗技术和相关细胞产品规范化、规模化、产业化。特色：

Establishment of a comprehensive cell therapy technology translation and application platform in all regions to prepare, test, and evaluate different types of cell products for biotherapy. Positioning:

A strict quality control and assessment system to set up ensure uniformity, stability, controllability, effectiveness and traceability of cell preparations; and promote the standardization, mass production and industrialization of the latest biotherapy technologies. Characteristics:

从人员资质、仪器设备配置、耗材、工艺流程、发放标准等全部采用统一标准，以保证供给该区域所有科研机构和临床应用机构的细胞有效性和安全性，拥有独立质量控制管理中心。

(1)Unified standards: Independent quality control centers following unified standards for employee qualification, apparatus c o n f i g u r a t i o n , c o n s u m a b l e s, t e c h n o l o g i c a l p r o c e ss e s a n d distribution ensure effectiveness and safety of cells provided to regional research institutes and clinical applications.优势： Advantages:①标准统一：

每个区域只建设一个区域细胞制备中心，安全监管工作量大为减少，监管成本将大大降低。 (2) Centralized management and lower regulatory costs Only one regional cell manufacturing center per region lowers workload and cost for safety supervision.②集中管理，

监管成本降低：

细胞保存、细胞制备与细胞治疗具有不同的技术规范与标准，术业各有专攻，由专业的机构建设区域细胞制备中心，医疗机构专注于疾病的细胞治疗符合科学发展规律。 (3) Efficient labor division and cooperation Professional institute estanlishs a regional cell manufacturing center and handle the different specifications and standards of cell banking, preparation and therapy, allowing medical institutes to concentrate on treating disease with cell therapies in compliance with scientific regulations.③专业分工，

协同互补：

产品与服务

PRODUCTS
AND
SERVICES

细胞储存服务

“综合细胞库+区域细胞制备中心”网络是目前世界上少有的超大规模自体细

胞储存与制备服务平台，专注、专业、专一致力于为每个家庭提供包括脐带、

脂肪、乳牙、胎盘、羊膜等来源的干细胞以及人外周血来源的免疫细胞等不同

组织来源的特定的人类细胞系储存服务。

脐 带

Umbilical cord

胎 盘

Placenta

外周血

Peripheral blood

乳 牙

Deciduous teeth

脂 肪

Adipose

Beike's “Integrated cell bank + regional cell manufacturing center” network is one of the

few large scale somatic cell storage and preparation service platforms in the world. It is

dedicated, professional, and fully committed to provide every family with cell storage

services of specific human cells from different tissues, including stem cells from the

umbilical cord, fat, deciduous teeth, placenta, amniotic membrane and other sources, and

immune cells from peripheral blood. Beike Biotechnology is your trustworthy cell bank.

Cell banking services

09

北科生物“以质量为先”，一直全方位高标准严格按照AABB相关标准开展干细胞、免疫细胞

等多种细胞的采集、运输、制备、质量检验管理、储存、发放、设备维护、人员培训等业务工

作，同时不断完善和规范细胞库的各项规章制度和管理措施，定期落实内部监查稽核工作，让

储存在北科生物细胞库的细胞能得到行业内全球最高标准的质量保障。

北科生物一直致力质量管理体系的建设。北科生物“出品”的每一份细胞涉及680+份标准文

件，870+份质量记录，最高达910+项质量控制节点的检测或确认，保障每一份细胞具有可回

溯性、可追踪性，用实力让储户安心。

Beike prioritizes quality, and always maintains high standards in strict accordance with the AABB on stem

cell, immune cell and other cell collection, transportation, preparation, quality inspection, storage,

distribution, equipment maintenance, personnel training. Beike constantly improving and standardizs

guidelines, regulations and management measures, and regularly carries out internal oversight, ensuring

that cells stored at Beike cell bank are at the world's highest standards of quality assurance within the

industry.

严 谨 · 创 新 · 关 爱 · 服 务

Beike Biotechnology has been committed to building its quality management system. Each cell “produced”

by the company involves 680+ standard documents, 870+ quality records, and up to 910+ points of

inspection or confirmation for quality control. Such a quality control system ensures the traceability of cell

growth and guarantees the safety of the cells for our storage users.

10

细胞制备服务

北科生物引领制定细胞制备行业标准，建立严格完善的质控体系，掌

握先进的细胞技术，携手国际一流的科研机构，服务于北科客户！我

们为广大市民、科研单位、医疗机构等提供各类标准统一的细胞制品

的制造、检验、鉴定等为一体的综合性细胞生物技术服务。

Beike leads the establishment of industry standards for cell preparation,

setting up strict quality control systems, applying advanced cell technologies,

working together with first-class international scientific research

institutions, and serving Beike customers.We provide a wide range of

integrated cell biotechnology services including cell preparation, inspection,

identification and other services all at standardized levels to citizens,

scientific research units, medical institutions and more.

Cell manufacting services

11

严 谨 · 创 新 · 关 爱 · 服 务

细胞治疗技术研究与临床转化

Joint national-local personalized cell therapy technology engineering

laboratory;

Innovation and development platform for the biological treatment

technology industry;

Beike Biotechnology has cooperated with more than 100 domestic and

international research and medical institutions in cell therapy, providing

personalized cell therapies for over 100,000 patients with refractory diseases

from more than 70 countries such as the United States, Canada, Britain and

Japan, and receiving recognition in its treatment results and cell quality by

the international academic community.

Cell therapy research and clinical translation

个体化细胞治疗技术国家联合地方工程实验室；

生物治疗技术产业领域的“双创平台”；

北科生物与国内外近百家科研及医疗机构开展细胞治疗技术研究合

作，为2万多例、10万多人次难治性疾病患者的细胞治疗提供标准

化、可追溯的个体化细胞制备技术服务，包括来自美国、加拿大、

英国、日本等70多个国家的患者，良好的细胞制备质量及显著的效

果获得国际同行认可。

12

13 ISO14001

ISO14001：要求组织通过建立环境管

理体系来达到支持环境保护、预防污染

和持续改进的目标，并通过取得第三方

认证机构认证的形式，向外界证明其环

境管理体系的符合性和环境管理水平。

通过ISO14001质量管理体系认证。

Beike Biotechnology has been certified by

ISO 14001 Quality Management System

ISO 14001 requires organizations to attain

the goal of supporting environmental

protection, pollution prevention and

continuous improvements by building an

environmental management system as well

as to prove the conformity of their

environmental management system and

environmental management level by passing

the certification of the third-party

certification body.

ISO9001

ISO9000族 标 准 是 “ 国 际 标 准 化 组

织 ” （ ISO） 提 出 的 概 念 ， 是 指 由

ISO/Tc176（“国际标准化组织质量

管理和质量保证技术委员会”）制定

的国际标准。

Beike Biotechnology has been certified by

ISO 9001 Quality Management System

The ISO 9000 family of standards is

p r o p o s e d b y t h e I n t e r n a t i o n a l

Organization for Standardization (ISO)

and enacted by the ISO Technical

Committee (ISO/TC176).

通过ISO9001质量管理体系认证。

质量管理体系

QUALITY
MANAGEMENT
SYSTEM

14

OHSAS18001

OHSAS18001：是20世纪80年代后期

在国际上兴起的现代安全生产与职业

健康安全管理模式，它与ISO9001和

ISO14001等标准规定的管理体系一并

被称为后工业划时代的管理方法。

通过OHSAS18001质量管理体系认证。

Beike Biotechnology has been certified by

OHSAS 18001 Quality Management

System.

OHSAS18001 is a modern safe production

management model that emerged in the

world in the late 1980s. It is referred to as a

post-industrial epoch-making management

system along with the management systems

ISO 9001 and ISO 14001.

AABB

中国大陆第一家通过全球先进的输血和细

胞治疗技术联盟（AABB）认证的单位。

AABB : 全球先进的输血和细胞治疗

技术联盟（原名：美国血库协会），

是全世界水平最高的细胞治疗服务标

准认证机构。

Beike Biotechnology is the first

enterprise certified by AABB-the world's

advanced blood transfusion and cell

therapy technology alliance-in Mainland

China

AABB: the world's advanced transfusion

and cell therapy technology alliance

andformerly known as the American

Association of Blood Banks, is the

highest-level cell therapy standard

certification body in the world.

ISCT

中国第一家获得国际细胞治疗协会

(ISCT)认可的会员单位。

ISCT：国际细胞治疗协会，是致力于

细胞研究、制备、处理及临床移植的

国际专业组织。

Beike Biotechnology is the first member

unit approved by the International

Society for Cellular Therapy (ISCT) in

China

ISCT: International Society for Cellular

Therapy is an international professional

organization devoted to cell research,

preparation and processing, as well as

clinical transplantation.

严 谨 · 创 新 · 关 爱 · 服 务

15 技术优势 TECHNICAL
ADVANTAGES

Through strategic licensing, acquisition and independent R&D, Beike has

established an important strategic position in the field of immunotherapy.

Beike possesses multiple cutting-edge and innovative immunotherapy

technologies and products. ALT-803 is considered by the NCI to be the most

promising interleukin drug for cancer treatment. MAR-based (MHC Antigen

Receptor) antibodies and bi-specific antibodies, and MAR-T and MAR-NK

cell therapies have shown to be more effective than conventional CAR-T,

TCR-T and bi-specific antibodies in treating hematologic and solid tumors,

viral infections and other diseases.

Advanced immune cell therapy technologies

先进的免疫细胞治疗技术

通过战略性授权，并购和自主研发，北科生物在免疫治疗领域占有

重要的战略地位。北科生物拥有多种国际先进的免疫治疗技术和产

品。ALT-803被NCI认为是最有希望治愈癌症的白介素类药物。在主

要组织相容性复合物抗原识别受体研发平台开发MAR-T、MARNK细胞治疗比目前的常规的CAR-T、TCR-T和双特异性抗体，在恶

性血液病、实体瘤和病毒感染等疾病方面具有更显著的治疗优势。

16

严 谨 · 创 新 · 关 爱 · 服 务

在过去的几年，T细胞嵌合抗原受体技术已经在肿瘤治疗领域取得了革命性的突破，而且已经改变了传统的肿瘤

治疗方法。嵌合抗原受体技术利用基因工程技术改造T细胞，使T细胞表面表达识别肿瘤抗原受体，增强T细胞识

别肿瘤抗原的能力，削弱肿瘤的免疫耐受性。嵌合抗原受体技术已经显示出了巨大的癌症治疗潜力。目前的嵌合

抗原受体只能识别细胞表面抗原。然而，80-90%的癌症抗原是细胞内抗原，嵌合抗原受体无法识别。在MAR技

术平台下，北科将开发一系列的细胞治疗产品，包括MAR-T（基于MAR的CAR-T技术）和MAR-NK。以MAR为

识别受体的CAR-T和CAR-NK细胞治疗与常规的CAR-T相比，MAR-T能够识别的抗原谱更广，同时又比TCR-T技

术具有更强的特异性和亲和力，安全性更高。

In the past few years, T cell chimeric antigen receptor (CAR-T) technology has led to a revolution in the oncology field and

changed the landscape of medical oncology. CAR-T technology uses genetic engineering to have T cells express antigen

receptors, enhancing T cells to target cancer antigens and overcoming immunotolerance. CAR-T has shown great potential in

cancer treatment. CAR-T technology in its current form can only target cancer antigens on the cell surface. However, 80-90%

of cancer targets are intracellular, which CAR-T

cannot access. Based on MAR technology, Beike will launch a series of cell therapy products, including MAR-T (MAR based

CAR-T) and MAR-NK. MAR-based CAR-T cell and CAR-NK cell therapy have advantages as compared to regular CAR-T –

they have a much wider

spectrum of target binding. Compared with TCR-T technology, it also has better specificity and affinity, and should be much

safer.

MAR-based cell therapy

基于MAR的细胞治疗

美国国立肿瘤研究所曾经认为IL-15是最有可能治愈肿瘤的白介素类药物。ALT-803是重组的IL-15超级激动剂

蛋白。它能够有效的刺激免疫细胞抵抗恶性血液病，实体瘤和病毒感染的细胞。目前Altor公司已经在美国开

展多项针对多种癌症治疗的ALT-803临床试验。除了ALT-803治疗药物以外，北科生物同时以ALT-803为基础

开发803细胞培养液。803细胞培养液能够显著增强T细胞和NK细胞在体内和体外的存活率。

As a result of encouraging pre-clinical studies, the NCI considers IL-15 as one of the most promising therapeutic agents in

cancer treatment. ALT-803 is a recombinant human superagonist interleukin-15(IL-15). It is a potent immunotherapeutic

agent capable of activating immune cell responses against hematologic and solid tumors and virally infected cells. ALT-803 is

currently in clinical development and is being evaluated by Altor in multiple U.S.-based clinical trials in various cancer

indications. In addition to the ALT-803 therapeutic drug, Beike is also developing 803 cell culture medium. The 803 cell

culture medium will significantly enhance the persistence of T and NK cells ex vivo and in vivo.

ALT-803

ALT-803

北科专利：

申请132项细胞技术领域相关专利，

106项获得授权，部分专利列表如下：

application for 132 cell technology

patents, 106 approved,with part of

the patents listed as follows:

腹侧急性闭合性脊髓损伤动

物模型的专用腹侧打击器

ZL200710077438.x

干细胞冻存液及干细胞的冻

存方法

ZL200910167171.2

一种可植入的披膜三维载体

及其制备方法

ZL201010224488.8

一种高效诱导人类体细胞重

编程为多潜能干细胞方法

ZL201010593844.3

单个核细胞培养液 ZL201110221115.X

细胞转核诱导体细胞成多能

二倍体干细胞的方法

ZL201110243239.8

通过mRNA诱导体细胞为多

能干细胞的方法

ZL201110243254.2

一种分离单个核细胞的方法

和装置

ZL200810089682.2

能诱导干细胞向成骨细胞分

化的微小RNA及其应用

200810225514

一种高效诱导多能性干细胞

的重组腺病毒载体、使用该

载体的诱导方法及其用途

ZL200910045714.3

一种预防肿瘤复发和抑制肿

瘤生长的寡聚核酸及其应用

ZL201010137856.5

体内和体外再生细胞的方法 ZL200680046641.4

干细胞在制备治疗帕金森病

的制剂中的用途

Zl2013101668044

脐带间充质干细胞在制备治

疗红斑狼疮的制剂中的用途

ZL201310138408.0

帕金森氏病动物模型平台及

其在药物筛选中的用途

2012105855609

一种具有双特异性抗体的细

胞CTL（BiAT）、其制备方

法及其应用

201310442787.2

一种可用于肝衰竭治疗的经

HGF基因修饰的UCMSC制备

方法

201410841610.4

牙齿来源间充质干细胞体外分

离与培养方法

201410841531.3

一种制备绒毛膜间充质干细胞

的方法

201410795197.2

一种制备蜕膜间充质干细胞的

方法

201410795200.0

间充质干细胞外泌体在制备治

疗肺纤维化的药物制剂中的应用

201510091820.0

脐带间充质干细胞在制备治疗

肺纤维化的药物制剂中的应用

201510091984.3

一种用于免疫治疗的EB病毒

LMP2A串联表位肽及其作用 201510963795.0

一种抗CD16A抗原和抗MUC1

抗原的双特异性抗体 201510974016.7

分泌TRAIL的间充质干细胞及

其治疗脑瘤的用途

201610176358.9

一种人脐带间充质干细胞的制

备方法

ZL201010528733.4

一种脐带保存液及其制备方法 Zl2011102193931

一种脐带血分离二联袋分离造

血干细胞的方法

Zl2011102194084

脐带间充质干细胞数字化自动

生产系统

ZL2011101767125

经血间充质干细胞的培养方法 201410836460.8

脐带间充质干细胞数字化自动

生产方法

ZL2011101766936

专利名称 专利号 专利名称 专利号

201410531197.1

可分泌型TRAIL蛋白构建物和

表达载体

人羊膜间充质干细胞的分离

及培养方法及医用组合物

ZL200610033007.9

研发优势

RESEARCH
AND

DEVELOPMENT
ADVANTAGE

Beike patents:

17

严 谨 · 创 新 · 关 爱 · 服 务

北科论文：

发表学术文章百余篇，部分论文列表：

Beike articles：

100+ published academic articles, with some listed as follows:

论 文 名 称 发 表 杂 志

The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated

gene regulation.

Direct-current electrical field guides neuronal stem/progenitor cell migration

Targeted tumor gene therapy based on loss of IGF2 imprinting.

Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE

Autologous Stromal Vascular Fraction Cells: A Tool for Facilitating Tolerance in

Rheumatic Disease

MiRNA-20a promotes osteogenic differentiationof human mesenchymal stem cellsby

co-regulating BMP signaling

Human umbilical cord mesenchymal stromal cells mitigate chemotherapy-associated

tissue injury in a pre-clinical mouse model

Promotion of the induction of cell pluripotency through metabolic remodelingby

thyroid hormone triiodothyronine-activated PI3K/AKT signal pathway.

C-peptide increase in chronic type 1 diabetic patients treated with autologous bone marrow

cell transplantation through pancreatic artery catheterization: three years follow-up

Early immunotherapy using autologous adult stem cells reversed anti-pancreatic-islets effect

in recently diagnosed type 1 diabetes mellitus: preliminary results.

Intrachromosomal Looping Is Requiredfor Activation of Endogenous Pluripotency

Genesduring Reprogramming.

Transplantation of human cord blood mononuclear cells and umbilical cord-derived

mesenchymal stem cells in autism.

Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor

cell lines

Umbilical cord mesenchymal stem cell transplantation in active and refractory

systemic lupus erythematosus: a multicenter clinical study.

Human umbilical cord mesenchymal stromal cells rescue mice fromacetaminophen-induced

acute liver failure.

Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in

mouse by regulating peripheral immunoinflammation.

Hematopoietic recovery of acute radiation syndrome by human superoxide

dismutase-expressing umbilical cord mesenchymal stromalcells.

Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute

myocardial infarction: double-blind, randomizedcontrolled trial.

Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy inPatients with Severe

Cerebral Palsy: A Retrospective Study

Characterization and transplantation of enteric neural crest cells from human induced

pluripotent stem cells

Cytotherapy. 2014,16(9):1207-19.

PLOS One, 2008, 3(3):e1719

Stem Cells, 2008, 6(8):2193-200

Cancer Biology &Therapy,

2010, 10(3):290-298.

Nature Reviews Rheumatology,

2010, 6:486–489

Cellular Immunology,2010, 264:7-17

RNA Biology, 2011, 8(5):829-838

Cytotherapy,2012, 14(4):412-422

Biomaterials,2012, 33(22):5514-5523

Stem Cell Discovery, 2013, 3(1):56-63

Medical Science Monitor,2013, 19.

Cell Stem Cell,2013, 13(1):30-35

Journal of Translational Medicine,

2013, 11:196

Human Molecular Genetics,

2014,23(1):117-28.

Arthritis Research & Therapy,

2014 Mar 25;16(2):R79.

Brain Research. 2015,(12)1594:293-304.

Cytotherapy. 2015,17(4):403-17.

BMC Medicine.2015 Jul 10;13:162.

Stem Cells International

Volume 2015,Article ID 325652.

Molecular Psychiatry ,2016,(00): 1-10

18

●北科生物的全球战略合作伙伴Altor Bioscience Corp参与发起

“肿瘤登月2020”计划的启动

●与Altor Bioscience Corp就新型重组二聚体蛋白复合物生物制

品——ALT-803达成跨国战略合作（ALT-803：北美肿瘤医师

协会排名第一的肿瘤免疫创新药物）

●国际细胞治疗协会 (ISCT) 会员

●受到国际资本追捧

●Altor Bioscience Corp, a strategic partner of Beike Biotechnology and a

participant in the launch of Cancer Moonshot 2020

●Cross-border strategic cooperation with Altor Bioscience Corp on ALT803 (ALT-803: ranked first among innovative anti-tumor drugs by the

Oncologist Association of North America)

●Member of ISCT

●Capital investments

国际合作

INTERNATIONAL
COOPERATION

19

●The world's first enterprise releasing the largest collection of research data on the clinical safety of human umbilical cord blood cells

●The world's first case of using umbilical cord stem cells to help a blind patient recover their sight

●The world's first case of using umbilical cord stem cells to help a patient with systemic lupus erythematosus (SLE) regain their health

●The first enterprise approved as a national high-tech enterprise in China's stem cell field

●The first enterprise jointly certified by ISO 9001, ISO 14001 and OHSAS 18001 Quality Management Systems in China's stem cell field

●The first lab certified by ISO17025 (CNAS) in China's stem cell field

●One of the first umbilical cord mesenchymal stem cell banks certified by AABB in the world

●The first umbilical cord blood stem cell bank certified by AABB in Mainland China

●The first stem cell bank that passed site reexamination accreditation by AABB in Mainland China

●The first enterprise in the history of AABB that earned accreditation of four products at the same time

●The first peripheral blood immune cell storage technology quality management system certified by AABB in the world

●The first regional manufacturing facility for personalized cell therapy approved and built in China

资质荣誉

HONORS
AND
QUALIFICATIONS

严 谨 · 创 新 · 关 爱 · 服 务

●世界上第一家公布最大规模人脐血单个核细胞临床安全性研究数据的企业

●世界上第一例人脐带来源干细胞令失明的患者重见光明

●世界上第一例人脐带来源干细胞令系统性红斑狼疮(SLE)患者重拾健康

●中国干细胞领域第一家获得国家高新技术企业认定的企业

●中国干细胞领域第一家同时拥有ISO9001、ISO14001和OHSAS18001质量管理体系证书的企业

●中国干细胞领域第一家通过中国合格评定国家认可委员会（CNAS）ISO17025认可的实验室

●世界第一批获得AABB认证的脐带间充质干细胞库

●中国大陆第一家通过AABB认证的脐血干细胞库

●中国大陆第一家通过AABB现场复审认证的干细胞库

●AABB认证史上第一家四个产品同时通过审核认证的单位

●人外周血免疫细胞储存应用技术质量管理体系全球第一家通过AABB认证

●中国第一个获得批复并启动建设的区域细胞制备中心

北科生物在细胞领域不断创造着中国第一和世界第一

Beike Biotechnology has achieved many firsts in the cell industry both in

China and in the world

20

获得的资质

Beike's qualifications 北科生物细胞产业发展获得国家科技部、发改委及多个省市各级政府的大力支持，且

北科生物的干细胞与再生医学产业项目被列入各地产业重点突破工程项目。

Beike's stem cell industry development has obtained strong support from the National Ministry of

Science and Technology, Development and Reform Commission (NDRC) and a number of

provinces' and cities' government, Beike's stem cell and regenerative medicine industry projects

have been included in the focus on industry breakthrough projects.

深圳市

北科细胞工程研究所

Chinese Industry and Innovative Technology Strategic Alliance of Stem Cells and Regenerative Medicine

Vice Chairman Unit

Ministry of Science and Technolgy of the People’s Republic of China

广东省干细胞再生医学新生物

广东省科学技术厅

工程技术研究开发中心

深圳市发展改革委员会

北科总部及国际干细胞研发基地

深圳市

干细胞工程技术研究开发中心

深圳市

干细胞与再生医学工程实验室

免疫细胞质量分析检测服务平台

21

未来愿景

VISIONS

一个家庭、一个群体、一种生存状态的改变……

Changes in the state of families, groups and lives……

严 谨 · 创 新 · 关 爱 · 服 务

22

推动生物治疗技术临床转化的领军企业，

为改善人类健康不懈努力！

推动生物治疗技术临床转化的领军企业，

为改善人类健康不懈努力！

The leader in promoting clinical translation of biotherapy technologies,

Making unremitting efforts to improve human health!

The leader in promoting clinical translation of biotherapy technologies,

Making unremitting efforts to improve human health!